What are the WHO guidelines on obesity drugs for children under 10?
The sources here describe pediatric obesity drugs mainly for teens, with no WHO position and no evidence for children under 10.
Covers: This page covers the WHO's recommendations and evidence on pharmacological treatment of obesity in children under 10, including when drugs may be considered, which medications are discussed, and how guidelines differ from those for older children and adults. It does not provide medical advice or cover non-WHO guidelines in detail.
3 free full reads left this month. Join or upgrade
The short answer
Interpretation AI-prepared starting mapNo source here states a current World Health Organization recommendation on obesity drugs for children under 10. The material available is clinical guidance and review literature from endocrine and obesity journals. It describes pediatric obesity as affecting about 17% of US children and adolescents, sets obesity at BMI at or above the 95th percentile, and reports that pharmacotherapy use is under 2% among eligible adolescents. Randomized pediatric trials of liraglutide and semaglutide show clinically meaningful BMI reduction, with the largest mean effect for semaglutide in adolescents, but long-term effects on growth, puberty, bone health, body composition and weight maintenance remain uncertain. No randomized trial has tested tirzepatide in pediatric obesity without diabetes.1234
- Evidence 18
- Interpretation 5
In brief
Randomized pediatric trials show clinically meaningful BMI reduction with liraglutide and semaglutide, with the largest mean effect for semaglutide in adolescents.4
Evidence-backedLong-term effects on growth, puberty, bone health, body composition and weight maintenance remain uncertain, and no randomized trial has tested tirzepatide in pediatric obesity without diabetes.4
Evidence-backedEven among eligible adolescents, pharmacotherapy use is under 2%, with low comorbidity screening and infrequent lifestyle-intervention referrals.3
Evidence-backed
At a glance
The picture in numbers
Live · updated just now
17%
17 in every 100
2%
2 in every 100
- Overweight85 percentile
- Obesity95 percentile
The evidence behind it
5 sources- Reviews of many studies1
- Other studies and data4
When it was published
Newest from 2026
| Source | Kind | Year |
|---|---|---|
| Prevention and Treatment of Pediatric Obesity: An Endocrine Society Clinical Practice Guideline Based on Expert Opinion | Other studies and data | 2008 |
| Pediatric Obesity—Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline | Other studies and data | 2017 |
| Prevalence and Predictors of Guideline Concordant Pediatric Obesity Care: A Narrative Review. | Reviews of many studies | 2026 |
| Clinical guidelines «Obesity in children» | Other studies and data | 2021 |
| GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Pediatric Obesity: From Neuroendocrine Mechanisms to Clinical Application. | Other studies and data | 2026 |
The community around it
- Contributions
- 0
- People
- 0
- Following
- 0
Nobody has added anything yet. Experience, evidence or a different view would show up here.
What it means for you
Which fits you?
Pick the situation closest to yours. Each answer says what it rests on.
If you are looking for the WHO position on obesity drugs for a child under 10
the material here does not contain a WHO recommendation, so treat any specific claim about WHO guidance as unverified until a WHO document is checked directly.14
InterpretationIf you are weighing drug treatment for a child and want to know what the pediatric evidence covers
the randomized evidence described is for liraglutide and semaglutide, with the largest mean BMI effect reported in adolescents, and long-term effects on growth, puberty, bone health and weight maintenance are described as uncertain.4
Evidence-backedIf you are considering tirzepatide for a child with obesity but without diabetes
no randomized trial has evaluated it in pediatric obesity without diabetes, so pediatric efficacy and safety are not established by the material here.4
Evidence-backedIf you are assessing a child's weight status
obesity is defined as BMI at or above the 95th percentile and overweight as at or above the 85th but below the 95th, with comorbidity evaluation from the 85th percentile and routine endocrine studies only if height velocity is attenuated or inappropriate for family background or pubertal stage.2
Evidence-backedIf you are planning care and wondering whether drug treatment is being used in practice
reported pharmacotherapy use is under 2% among eligible adolescents, with low comorbidity screening and infrequent lifestyle-intervention referrals, and barriers include provider hesitancy, resource limits and systemic inequities.3
Evidence-backedIf you are thinking about how drug treatment fits with other care
incretin-based therapies are described as needing integration with nutritional, behavioural, psychological and family-based care rather than standing alone.4
Evidence-backedThe full story · 2 chapters
01
What the available guidance and evidence cover
AI summary:Guidance covers pediatric obesity definitions, rare endocrine causes, incretin drug trials in teens, and very low real-world uptake.
Evidence-backed: Pediatric obesity is described as an ongoing international health concern affecting roughly 17% of US children and adolescents, with genetic susceptibility shaped by environment from before birth through adolescence; endocrine causes of obesity are rare and usually accompanied by attenuated growth patterns.1
Evidence-backed: Obesity is defined as BMI at or above the 95th percentile, with overweight at or above the 85th percentile but below the 95th. Routine endocrine studies are not recommended unless height velocity is attenuated or inappropriate for family background or pubertal stage; children with BMI at or above the 85th percentile should be evaluated for obesity-associated comorbidities.2
Evidence-backed: Incretin-based therapies act centrally and peripherally to reduce appetite, delay gastric emptying and enhance glucose-dependent insulin secretion, and are proposed to be integrated with nutritional, behavioural, psychological and family-based care rather than used alone.4
Evidence-backed: Randomized pediatric trials show clinically meaningful BMI reduction with liraglutide and semaglutide, with the largest mean effect reported for semaglutide in adolescents. Tirzepatide has shown greater weight-loss efficacy than selective GLP-1 receptor agonism in adults, but no randomized trial has evaluated it in pediatric obesity without diabetes.4
Evidence-backed: Screening for comorbidities such as dyslipidemia, diabetes and metabolic dysfunction-associated steatotic liver disease remains low despite longstanding recommendations, and referrals to intensive health behaviour and lifestyle interventions are infrequent. Pharmacotherapy use is under 2% among eligible adolescents and bariatric surgery referrals remain rare.3
Evidence-backed: Barriers to guideline-concordant care include provider hesitancy, resource limitations and systemic inequities; facilitators include electronic health record integration, multidisciplinary teams and expanded insurance coverage.3
Evidence-backed: Clinical guidelines for childhood obesity are presented as the practitioner's main working tool, covering epidemiology, classification, diagnosis and treatment on evidence-based principles.5
Interpretation: Read together, these sources describe a field where drug treatment is discussed mainly for adolescents, where uptake is very low even among eligible adolescents, and where the durability and developmental safety of these drugs are unresolved. None of them states a WHO position, and none isolates children under 10 as a group with its own pharmacological recommendation.431
Should obesity medications be used in children under 10 years old?
Your individual response is private. Only totals are shown.
02
How guidance differs by age
AI summary:Trial evidence is concentrated in adolescents, with no equivalent randomized evidence for children under 10.
Interpretation: The reported trial evidence for GLP-1 receptor agonists in pediatric obesity is concentrated in adolescents, where the largest mean BMI reduction was seen with semaglutide. The sources do not report equivalent randomized evidence for children under 10, so any extrapolation downward is not supported by the material here.4
Evidence-backed: Long-term effects on growth, puberty, bone health, body composition and weight maintenance remain uncertain, which matters more the younger the child. This is a stated limitation of the pediatric incretin evidence rather than a finding about any specific age threshold.4
Evidence-backed: Diagnostic thresholds and comorbidity screening are framed for children generally, using BMI percentiles and height-velocity and pubertal-stage caveats rather than an age cut-off for drug treatment.2
Ask this Sylo
Still wondering about something?
Answers come only from this page's reviewed material, with citations, and say plainly when the page doesn't cover it yet.
Behind this page
Who's adding to it, where it comes from, how it changed and what would make it better. Always open to everyone.
Discussion
Sources
Numbers match the citations in the article. A working link isn't proof that a page supports a claim; check the quoted passage and date.
- 1Pediatric Obesity—Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice GuidelineThe Journal of Clinical Endocrinology & Metabolism (Styne et al.)Published Jan 31, 2017Checked Oct 7, 2026
“Pediatric obesity remains an ongoing serious international health concern affecting ∼17% of US children and adolescents, threatening their adult health and longevity. Pediatric obesity has its basis in genetic susceptibilities influenced by a permissive environment starting in utero and extending through childhood and adolescence. Endocrine etiologies for obesity are rare and usually are accompanied by attenuated growth patterns.”
- 2Prevention and Treatment of Pediatric Obesity: An Endocrine Society Clinical Practice Guideline Based on Expert OpinionThe Journal of Clinical Endocrinology & Metabolism (August et al.)Published Sep 10, 2008Checked Oct 7, 2026
“We recommend defining overweight as body mass index (BMI) in at least the 85th percentile but < the 95th percentile and obesity as BMI in at least the 95th percentile against routine endocrine studies unless the height velocity is attenuated or inappropriate for the family background or stage of puberty; referring patients to a geneticist if there is evidence of a genetic syndrome; evaluating for obesity-associated comorbidities in children with BMI in at least the 85th perce…”
- 3Prevalence and Predictors of Guideline Concordant Pediatric Obesity Care: A Narrative Review.Current obesity reports (Orr et al.)Published Apr 14, 2026Checked Oct 7, 2026
“Screening for comorbidities such as dyslipidemia, diabetes, and metabolic dysfunction-associated steatoic liver disease (MASLD) remains low despite longstanding recommendations. Treatment-related KASs (11–13) show significant gaps: referrals to intensive health behavior and lifestyle interventions are infrequent, pharmacotherapy use is < 2% among eligible adolescents, and bariatric surgery referrals remain rare. Barriers include provider hesitancy, resource limitations, and systemic inequities; facilitators include electronic health record integration, multidisciplinary teams, and expanded insurance coverage. Despite strong evidence supporting early and intensive treatment of pediatric obesity, guideline adoption remains inconsistent. Addressing structural barriers, improving provider education, and leveraging health system innovations are critical for implementation. Future research should evaluate effective implementation strategies, long-term outcomes of pharmacotherapy, and approaches to adapt guidelines to local contexts.”
- 4GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Pediatric Obesity: From Neuroendocrine Mechanisms to Clinical Application.International journal of molecular sciences (Myśliwczyk et al.)Published Sep 15, 2026Checked Oct 7, 2026
“We describe how GLP-1 receptor agonists act across central and peripheral tissues to reduce appetite, delay gastric emptying, and enhance glucose-dependent insulin secretion and examine the rationale for dual GIP/GLP-1 receptor agonism. Randomized pediatric trials demonstrate clinically meaningful BMI reduction with liraglutide and semaglutide, with the largest mean effect reported for semaglutide in adolescents; however, long-term effects on growth, puberty, bone health, body composition, and weight maintenance remain uncertain. Tirzepatide has shown greater weight-loss efficacy than selective GLP-1 receptor agonism in adults, but no randomized trial has evaluated it in pediatric obesity without diabetes. Incretin-based therapies should be integrated with nutritional, behavioral, psychological, and family-based care. Their future value will depend on durable efficacy, developmental safety, equitable access, and identification of patients most likely to benefit.”
- 5Clinical guidelines «Obesity in children»Problems of Endocrinology (Peterkova et al.)Published Nov 12, 2021Checked Oct 7, 2026
“Childhood obesity is an urgent problem of pediatric endocrinology due to the widespread occurrence, the development of metabolic complications and their steady tracking into adulthood. The developed clinical guidelines are the main working tool of the practitioner. They briefly and structurally present the main information about the epidemiology and modern classification of obesity, methods of its diagnosis and treatment based on the principles of evidence-based medicine.”
How it changed
Published 1 time since Oct 7, 2026.
- Version 2Oct 7, 2026Live now
AI-prepared Starting Map from live research.
- First published version.
Help improve it
The brief is open about what's uncertain. These are the specific gaps that new material would fill.
Open questions
What does WHO currently recommend, if anything, on pharmacological treatment of obesity in children under 10, and how is that recommendation worded?
No answers yet
Are there randomized trials of obesity drugs specifically in children under 10, and what do they show for BMI, growth and safety?
No answers yet
At what age, if any, do guidelines permit starting obesity pharmacotherapy in children, and on what evidence is that threshold based?
No answers yet
What are the long-term effects of GLP-1 and dual GIP/GLP-1 agonists on growth, puberty, bone health and weight maintenance in children treated before puberty?
No answers yet
How do access, cost and equity shape whether any recommended drug treatment is actually available to young children?
No answers yet
Around this topic
Sylos connect: narrower topics report up to broader ones, so what's learned in one place shows up where it matters.